PMID- 38104776
OWN - NLM
STAT- MEDLINE
DCOM- 20240131
LR  - 20240206
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 365
DP  - 2024 Jan
TI  - Selective homing of brain-derived reconstituted lipid nanoparticles to cerebral 
      ischemic area enables improved ischemic stroke treatment.
PG  - 957-968
LID - S0168-3659(23)00804-0 [pii]
LID - 10.1016/j.jconrel.2023.12.020 [doi]
AB  - Lipid nanoparticles (LNPs) hold great promise as carriers for developing drug 
      delivery systems (DDSs) aimed at managing ischemic stroke (IS). Previous research 
      has highlighted the vital role played by the lipid composition and biophysical 
      characteristics of LNPs, influencing their interactions with cells and tissues. 
      This understanding presents an opportunity to engineer LNPs tailored specifically 
      for enhanced IS treatment. We previously introduced the innovative concept of 
      reconstituted lipid nanoparticles (rLNPs), which not only retain the advantages 
      of conventional LNPs but also incorporate lipids from the originating cell or 
      tissue. Brain-derived rLNPs (B-rLNPs) exhibit significantly superior accumulation 
      within the cerebral ischemic region when compared to liver-derived rLNPs 
      (L-rLNPs). The homing effect of B-rLNPs was then employed to construct 
      3-n-butylphthalide (NBP) loaded DDS (B-rLNPs/NBP) for the treatment of IS. Our 
      results demonstrated that compared with free NBP, B-rLNPs/NBP can significantly 
      reduce infarct volume, neurological deficits, blood-brain barrier (BBB) leakage 
      rate, brain water content, neutrophil infiltration, alleviate pathological 
      structures, and improve the motor function in MCAO/R model. We also proved that 
      B-rLNPs/NBP showed further reinforced protective effects on the same model than 
      free NBP through the regulation of TLR4/MyD88/NF-kappaB (anti-inflammation) and 
      Bax/Bcl-2 (anti-apoptosis) pathways. This study offers a promising tool towards 
      improved IS treatment.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Han, Dan
AU  - Han D
AD  - Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of 
      Medical School, Nanjing University, Nanjing, Jiangsu, China; Nanjing Medical 
      Center for Clinical Pharmacy, Nanjing, Jiangsu, China.
FAU - Wang, Meihua
AU  - Wang M
AD  - Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of 
      Medical School, Nanjing University, Nanjing, Jiangsu, China; Nanjing Medical 
      Center for Clinical Pharmacy, Nanjing, Jiangsu, China.
FAU - Dong, Ningyu
AU  - Dong N
AD  - Department of Radiology, Nanjing Drum Tower Hospital, Affiliated Hospital of 
      Medical School, Nanjing University, Nanjing, Jiangsu, China.
FAU - Zhang, Jiaxing
AU  - Zhang J
AD  - School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China.
FAU - Li, Dingran
AU  - Li D
AD  - School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 
      Nanjing, Jiangsu, China.
FAU - Ma, Xiaoling
AU  - Ma X
AD  - School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 
      Nanjing, Jiangsu, China.
FAU - Ma, Ying
AU  - Ma Y
AD  - Jiangsu Institute for Food and Drug Control, Nanjing, Jiangsu, China.
FAU - Wang, Siliang
AU  - Wang S
AD  - Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of 
      Medical School, Nanjing University, Nanjing, Jiangsu, China. Electronic address: 
      wsl_dth@126.com.
FAU - Zhu, Yun
AU  - Zhu Y
AD  - Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of 
      Medical School, Nanjing University, Nanjing, Jiangsu, China. Electronic address: 
      zjuzhuyun@163.com.
FAU - Wang, Cheng
AU  - Wang C
AD  - School of Pharmacy, Changzhou University, Changzhou, Jiangsu, China. Electronic 
      address: wangc90@cczu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20231219
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Lipid Nanoparticles)
RN  - 0 (NF-kappa B)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Liposomes)
SB  - IM
MH  - Humans
MH  - *Ischemic Stroke/drug therapy
MH  - Blood-Brain Barrier
MH  - NF-kappa B
MH  - *Neuroprotective Agents/therapeutic use
MH  - *Stroke/drug therapy
MH  - *Liposomes
MH  - *Nanoparticles
OTO - NOTNLM
OT  - 3-n-butylphthalide
OT  - Drug delivery systems
OT  - Ischemic stroke
OT  - Reconstituted lipid nanoparticles
OT  - Selective homing
EDAT- 2023/12/18 00:42
MHDA- 2024/01/31 06:43
CRDT- 2023/12/17 19:27
PHST- 2023/08/24 00:00 [received]
PHST- 2023/12/11 00:00 [revised]
PHST- 2023/12/13 00:00 [accepted]
PHST- 2024/01/31 06:43 [medline]
PHST- 2023/12/18 00:42 [pubmed]
PHST- 2023/12/17 19:27 [entrez]
AID - S0168-3659(23)00804-0 [pii]
AID - 10.1016/j.jconrel.2023.12.020 [doi]
PST - ppublish
SO  - J Control Release. 2024 Jan;365:957-968. doi: 10.1016/j.jconrel.2023.12.020. Epub 
      2023 Dec 19.